Featured Publications
Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder
Schnakenberg Martin AM, Bartolomeo L, Howell J, Hetrick WP, Bolbecker AR, Breier A, Kidd G, O’Donnell B. Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder. European Archives Of Psychiatry And Clinical Neuroscience 2017, 268: 653-661. PMID: 28936548, PMCID: PMC7126185, DOI: 10.1007/s00406-017-0839-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAuditory PerceptionFemaleHallucinationsHumansMaleMiddle AgedSchizophreniaYoung AdultConceptsAuditory verbal hallucinationsSchizophrenia spectrum disordersAuditory perceptionSZ individualsFeature perceptionVerbal hallucinationsSpectrum disorderAuditory featuresImpaired auditory perceptionSchizophrenia Voices QuestionnaireBasic Auditory CapabilitiesTemporal order discriminationAuditory hallucinatory experiencesCognitive processingTone taskOrder discriminationHamilton ProgramHallucinatory experiencesGreater deficitsSZ groupAuditory hallucinationsAuditory capabilitiesPerceptionVoice QuestionnaireIntellectual impairment
2019
Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers
Martin A, Lysaker PH. Individuals with psychosis and a lifetime history of cannabis use show greater deficits in emotional experience compared to non-using peers. Journal Of Mental Health 2019, 29: 77-83. PMID: 30822177, DOI: 10.1080/09638237.2018.1487540.Peer-Reviewed Original ResearchConceptsEmotional Expressivity ScaleEmotional experienceSocial Functioning ScaleEmotional expressionAnticipatory pleasureLifetime cannabisSocial functioningGreater deficitsSocial functionCannabis useNon-using peersAnticipation of pleasureExperience of pleasurePoor social functionEmotional expressivityLifetime historyAnticipatory anhedoniaProsocial activitiesActive cannabisPleasure ScaleTemporal experienceHistory of cannabisFunctioning ScaleEarly psychosisPrevious research
2018
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D’Souza D, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 2018, 235: 1923-1932. PMID: 29619533, DOI: 10.1007/s00213-018-4885-9.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAffectAntipsychotic AgentsCannabidiolChronic DiseaseCognitionCognitive DysfunctionDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMental Status and Dementia TestsMiddle AgedOutpatientsPsychiatric Status Rating ScalesSchizophreniaSchizophrenic PsychologyTreatment OutcomeConceptsMATRICS Consensus Cognitive BatterySide effectsChronic schizophreniaAntipsychotic-treated patientsMovement side effectsFixed-dose studyPlacebo-treated subjectsWeeks of treatmentPANSS total scoreEffects of cannabidiolWorsening of moodNegative Syndrome ScaleAntipsychotic-treated outpatients× time effect× time interactionMCCB composite scoreOral cannabidiolCBD groupClinical trialsParallel groupPANSS scoresMethodsThis studyPsychotic symptomsConsensus Cognitive BatterySyndrome Scale
2017
The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition
Helle S, Løberg EM, Gjestad R, Martin A, Lysaker PH. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition. Psychiatry Research 2017, 250: 92-98. PMID: 28152399, DOI: 10.1016/j.psychres.2017.01.047.Peer-Reviewed Original ResearchConceptsSocial cognitionTheory of mindExecutive functionCannabis useBell-Lysaker Emotion Recognition TestEmotion Recognition TestExecutive Functioning ScaleBetter executive functionRegular cannabis useStructural equation modelingHinting testIllicit substancesNeurocognitive vulnerabilityRecognition testNeurocognitive performanceNeurocognitive deficitsCognitionEquation modelingFlexibility componentsAlcohol useFunctioning ScaleLifetime cannabisIndirect effectsPositive linkSchizophrenia
2011
The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories
Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.Peer-Reviewed Original ResearchConceptsAdverse eventsPost-study periodCareful subject selectionMinor adverse eventsPhysical adverse eventsFrequent side effectsLong-term followCannabinoid receptor systemFaster infusion rateCannabinoid receptor ligandsIntravenous THCPlacebo infusionCannabinoid systemInfusion rateStudy participationSide effectsAbuse liabilityHigh dosesReceptor systemΔ9-tetrahydrocannabinolInfusionPsychoactive effectsReceptor ligandsTest daySubjects